Growing community of inventors

Melrose, MA, United States of America

Perry Calias

Average Co-Inventor Count = 3.36

ph-index = 5

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 71

Perry CaliasMichael A Patane (3 patents)Perry CaliasGary Paul Cook (3 patents)Perry CaliasGary Cook (7 patents)Perry CaliasDavid Shima (4 patents)Perry CaliasAnthony P Adamis (4 patents)Perry CaliasMike Jaffe (3 patents)Perry CaliasKathleen M Campbell (3 patents)Perry CaliasMary A Ganley (1 patent)Perry CaliasMike Patane (0 patent)Perry CaliasMike Patane (0 patent)Perry CaliasDavid Shima (0 patent)Perry CaliasGary P Cook (0 patent)Perry CaliasPerry Calias (7 patents)Michael A PataneMichael A Patane (52 patents)Gary Paul CookGary Paul Cook (12 patents)Gary CookGary Cook (7 patents)David ShimaDavid Shima (4 patents)Anthony P AdamisAnthony P Adamis (4 patents)Mike JaffeMike Jaffe (3 patents)Kathleen M CampbellKathleen M Campbell (3 patents)Mary A GanleyMary A Ganley (1 patent)Mike PataneMike Patane (0 patent)Mike PataneMike Patane (0 patent)David ShimaDavid Shima (0 patent)Gary P CookGary P Cook (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Ophthotech Corporation (4 from 4 patents)

2. Eyegate Pharmaceuticals, Inc. (3 from 6 patents)

3. Eyetech Inc. (3 patents)


7 patents:

1. 10376463 - Ocular iontophoretic delivery of dexamethasone and formulations thereof

2. 9820935 - Delivery of corticosteroids through iontophoresis

3. 9149525 - Delivery of corticosteroids through iontophoresis

4. 8685397 - Combination therapy for the treatment of ocular neovascular disorders

5. 8206707 - Combination therapy for the treatment of ocular neovascular disorders

6. 8187597 - Combination therapy for the treatment of ocular neovascular disorders

7. 7759472 - Combination therapy for the treatment of ocular neovascular disorders

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/6/2025
Loading…